Breaking News Instant updates and real-time market news.

KORS

Michael Kors

$68.01

1.3 (1.95%)

, CPRI

Capri Holdings

$0.00

(0.00%)

16:16
09/25/18
09/25
16:16
09/25/18
16:16

Fly Intel: Wall Street's top stories for Tuesday

Stocks opened in positive territory as they tried to recapture their losses from yesterday. Without a catalyst, the market was unable to gather any upside momentum and crossed into negative ground. Despite the weakness today, the S&P is still on track for its best quarterly performance since 2013 with less than a week left in the third quarter. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rose 0.28% to 213.76 in July. The FHFA home price index rose 0.2% to 265.0 in July. Richmond Fed manufacturing index climbed 5 points to 29 in September. The Conference Board's consumer confidence index rose to 138.4 in September from a reading of 134.7 in August. In trade news, Reuters reported that U.S. Trade Representative Robert Lighthizer said that Canada is not making concessions needed to reach an agreement with the U.S. for a trilateral NAFTA and is running out of time before the White House moves forward with a Mexico-only deal. COMPANY NEWS: Michael Kors (KORS) gained 2% after announcing a definitive agreement to acquire all of the outstanding shares of Italian luxury fashion house Gianni Versace S.p.A. for a total enterprise value of approximately $2.12B. Upon the closing of the Versace acquisition, Michael Kors said it will change its name to Capri Holdings (CPRI)... In other M&A news, Sonic (SONC) announced an agreement to be acquired by Inspire Brands for $43.50 per share in cash in a transaction valued at approximately $2.3B, including the assumption of Sonic's net debt... Facebook (FB) was in focus after Instagram co-founder and CEO Kevin Systrom confirmed that he and co-founder and CTO Mike Krieger will step down from the company. According to the New York Times, the Instagram founders have disagreed with Facebook CEO Zuckerberg on a handful of recent product changes, including changes to comments and how posts are shared between the two networks... Shares of automakers General Motors (GM), Ford (F) and Fiat Chrysler (FCAU) were under pressure after German carmaker BMW (BMWYY) lowered its fiscal year revenue view for its Automotive segment and said it would not meet its target of achieving a flat pre-tax profit... Square (SQ) shares finished 10% higher after Nomura Instinet analyst Dan Dolev raised his price target on the stock to $125, a new high among Wall Street research firms. Additionally, the company introduced a new payroll app for employers. Following the payroll app news, shares of ADP (ADP) and Paychex (PAYX) moved lower. MAJOR MOVERS: Among the noteworthy gainers was XO Group (XOXO), which jumped 26% after it signed a deal to merge with WeddingWire in a transaction valued at $933M. Also higher was Ascena Retail (ASNA), which gained 12% after the parent of the Ann Taylor and Lane Bryant brands reported quarterly results. Among the notable losers was TG Therapeutics (TGTX), which dropped 44% after a safety review board said the company's UNITY-CLL trial ORR analysis can not be conducted. Also lower was CenturyLink (CTL), which fell 8% after reporting that CFO Sunit Patel will depart as of September 28 to join T-Mobile (TMUS) and lead the Sprint (S) merger and integration efforts. INDEXES: The Dow fell 69.84, or 0.26%, to 26,492.21, the Nasdaq gained 14.22, or 0.18%, to 8,007.47, and the S&P 500 declined 3.81, or 0.13%, to 2,915.56.

KORS

Michael Kors

$68.01

1.3 (1.95%)

CPRI

Capri Holdings

$0.00

(0.00%)

FB

Facebook

$164.94

-0.46 (-0.28%)

SQ

Square

$95.40

9.34 (10.85%)

PAYX

Paychex

$73.72

-0.84 (-1.13%)

ADP

ADP

$148.80

-0.32 (-0.21%)

SONC

Sonic

$43.46

6.85 (18.71%)

GM

General Motors

$33.57

-1.175 (-3.38%)

F

Ford

$9.39

-0.195 (-2.03%)

FCAU

Fiat Chrysler

$18.00

-0.315 (-1.72%)

BMWYY

BMW

$0.00

(0.00%)

XOXO

XO Group

$34.91

7.29 (26.39%)

ASNA

Ascena Retail

$4.47

0.45 (11.19%)

TGTX

TG Therapeutics

$5.13

-4.125 (-44.59%)

CTL

CenturyLink

$21.05

-1.85 (-8.08%)

TMUS

T-Mobile

$69.46

0.53 (0.77%)

S

Sprint

$6.40

0.01 (0.16%)

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 04

    Oct

  • 04

    Oct

  • 11

    Oct

  • 22

    Oct

  • 28

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

  • 13

    Nov

  • 26

    Nov

KORS Michael Kors
$68.01

1.3 (1.95%)

09/24/18
WELS
09/24/18
NO CHANGE
WELS
Market Perform
Versace not seen by many as ideal M&A target for Michael Kors, says Wells Fargo
Wells Fargo analyst Ike Boruchow said many investors seem puzzled by the negative reaction today in shares of Michael Kors to reports that the company may be near a deal to acquire Italian fashion company Versace for $2.35B. He believes the weakness is due to the speed with which such a deal would be made following the purchase of Jimmy Choo just 11 months ago and the fact that on the surface the reported deal would appear to be fairly dilutive. Versace "doesn't make for an ideal M&A target in the eyes of many shareholders," the analyst added. Boruchow thinks an acquisition at the terms reported could be 30c-40c dilutive to EPS in year one, not inclusive of dilution should the company halt their current buyback program, representing a 7-9% impact to EPS in year one, which he notes is a similar percentage impact as what the stock is seeing today. Boruchow keeps a Market Perform rating on Michael Kors shares, which are down 7.7% to $67.12 in afternoon trading.
08/09/18
ADAM
08/09/18
NO CHANGE
Target $90
ADAM
Buy
Michael Kors price target raised to $90 from $84 at Canaccord
Canaccord analyst Camilo Lyon raised his price target on Michael Kors to $90 from $84 following solid Q1 results. The analyst said the beat was due to broad based sales, gross margins, expense leverage, and a positive tax rate. He said the key elements of his Buy thesis are in place and trending upwards, strong free cash flow is being deployed for buybacks, and the shares are at an attractive valuation. Lyon reiterated his Buy rating on Michael Kors shares.
08/09/18
NOMU
08/09/18
NO CHANGE
Target $85
NOMU
Buy
Michael Kors price target raised to $85 from $80 at Nomura Instinet
Nomura Instinet analyst Simeon Siegel raised his price target for Michael Kors to $85 saying yesterday's Q1 results showed top-line strength and meaningful margin expansion. Kors has been "showing remarkable strides as one of the best Shrink to Grow stories," but its multiple is lagging meaningfully behind peers, the analyst adds. He reiterates a Buy rating on the shares.
08/17/18
PIPR
08/17/18
NO CHANGE
Target $71
PIPR
Neutral
Michael Kors price target raised to $71 from $66 at Piper Jaffray
Piper Jaffray analyst Erinn Murphy raised her price target for Michael Kors to $71 from $66 but maintained a Neutral rating following the company's Q1 results, telling investors in a research note that she continues to maintain her sidelined stance. Though she raised her estimates for Q2 and FY19/FY20 based on an improved Q1, she would like to see more evidence of a sustained improvement at retail.
CPRI Capri Holdings
$0.00

(0.00%)

FB Facebook
$164.94

-0.46 (-0.28%)

09/25/18
NOMU
09/25/18
NO CHANGE
Target $125
NOMU
Buy
Square price target raised to $125 from $86 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for Square (SQ) to $125 from $86 and keeps a Buy rating on the shares. The stock closed yesterday up 75c to $86.04. The analyst's analysis of Square's fundamentals indicates "buoyant" gross payment volume, revenue and marketing efficacy trends. The company's "fully cohesive solutions and rapid rate of innovation" suggest that it is en route to disrupt the global payments ecosystem, Dolev tells investors in a research note titled "Improving Momentum Means $125 Is Within Reach." He believes this is similar to the FANG stocks, or Facebook (FB), Amazon.com (AMZN), Netflix (NFLX) and Google (GOOG, GOOGL), that have "disrupted traditional markets with massive" global total addressable markets. Further, Dolev believes shares of Square are not too expensive when taking into account its "stellar" 45% expected three-year annual revenue growth, which he thinks "makes it screen more attractively than many payment peers and FANG stocks."
09/25/18
BARD
09/25/18
NO CHANGE
Target $195
BARD
Outperform
Facebook survey suggests stabilizing user engagement, says Baird
Baird analyst Colin Sebastian said his latest social media survey suggests stabilizing user engagement on the core Facebook app, following a period of declines. If accurate, the survey suggests concerns over an engagement and monetization-related slowdown may already be reflected in the shares. He also said Q3 estimates embed reasonable expectations for user growth. Sebastian reiterated his Outperform rating and $195 price target on Facebook shares.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
JPMorgan sees 'meaningful pressure' on Facebook shares from Instagram departures
JPMorgan analyst Doug Anmuth says the "surprising" departure of Instagram co-founders Kevin Systrom and Mike Krieger is concerning and likely to put "meaningful pressure" on shares of Facebook (FB) in the near-term. The analyst believes Instagram has been a strong growth driver for Facebook and has played a critical role in retaining younger users within the company's group of platforms and in competing with Snap (SNAP). While the exact rationale for the co-founders' departure is unclear, various press reports suggest it is related to Facebook management recently exerting more control over Instagram, Anmuth tells investors in a research note. The analyst has an Overweight rating on Facebook. The stock in premarket trading is down 2%, or $3.71, to $161.70.
09/25/18
RHCO
09/25/18
NO CHANGE
Target $200
RHCO
Buy
Instagram 'in a good place' after Systrom, Krieger resignations, says SunTrust
SunTrust analyst Youssef Squali maintained a Buy rating and $200 price target on Facebook following the departure of Instagram co-founders Kevin Systrom and Mike Krieger. In a research note to investors, the analyst notes that the departures are the "latest in a string" of high profile departures in recent months, including WhatsApp co-founders Jan Koum and Brian Acton and VP and General Counsel Colin Stretch, and follows a restructuring earlier this year that reorganized the entire company. Squali contends that Instagram is "in a good place" and is being left with "stable footing," as well as "impressive" growth in users as Stories DAUs, adding that product cadence has slowed and it is entering a new phase of its life. Squali feels a deeper integration with Facebook could lead to an improved advertising product and monetization, which Systrom and Krieger may have been more resistant to, and does not see any material changes at the Facebook unit in the near-term.
SQ Square
$95.40

9.34 (10.85%)

09/21/18
EVER
09/21/18
NO CHANGE
Target $101
EVER
Outperform
Square price target raised to $101 from $76 at Evercore ISI
Evercore ISI analyst Rayna Kumar raised her price target on Square to $101 and kept her Outperform rating citing the findings of her analysis of Square Cash App monetization. The analyst notes that the last two years saw the company launch new product features for the app including "Instant Deposit, the Square Cash Card, Bitcoin trading, and its reward program Boost", becoming a likely "material driver to both revenue and earnings over time". Kumar expects the app to contribute up to 16c to Square's FY20 EPS, 30c to FY21 EPS, and 40c in FY22 EPS, stating that the company's monetization strategy is in the "early innings".
09/25/18
JEFF
09/25/18
NO CHANGE
Target $88
JEFF
Hold
Square price target raised to $88 from $63 at Jefferies
Jefferies analyst John Hecht raised his price target for Square to $88 after taking a detailed look at the company's non-payments businesses. The analyst, however, keeps a Hold rating on the shares. Various sum-of-the-parts analyses points to current premium valuations for each segment, suggesting "strong growth and successful execution is likely priced-in," Hecht tells investors in a research note. While Square's Subscription & Services products are "no doubt well positioned," the stock's valuation remains full, Hecht contends.
09/25/18
BARD
09/25/18
NO CHANGE
BARD
Neutral
New Square payroll app more of a threat to Paychex than ADP, says Baird
Baird analyst Mark Marcon said that based on his conversations, and the reaction this afternoon in shares of ADP (ADP) and Paychex (PAYX) to Square's (SQ) announcement of a new payroll app, that it is "fair to say" the majority of investors had not considered Square as a potential competitor. While others have been in the space for years and the near-term real business impact from Square is likely to be minimal, the news does increase the visibility of emerging competition, said Marcon. Square's target is small companies so this is more of a competitive threat to Paychex than ADP, added the analyst, who has Neutral ratings on both legacy HCM providers.
PAYX Paychex
$73.72

-0.84 (-1.13%)

08/14/18
JPMS
08/14/18
DOWNGRADE
Target $76
JPMS
Underweight
Paychex downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tien-Tsin Huang downgraded Paychex to Underweight while raising his price target for the shares to $76 from $67.
08/14/18
JPMS
08/14/18
NO CHANGE
JPMS
JPMorgan shuffles ratings in Payments & Processors, upgrades Alliance Data
JPMorgan analyst Tien-tsin Huang rebalanced his ratings in the Payments & Processors while establishing 2019 price targets. With payments "increasingly being consumed and distributed via technology," the analyst continues to favor the "more modern, digital players." He believes the shift towards integrated payments and digital banking is in the early stages. Analyst Reginald Smith upgraded Alliance Data Systems (ADS) to Overweight from Neutral and raised his price target for the shares to $281 from $270. Smith thinks stock sentiment is nearing an inflection point as delinquency trends stabilize. Huang downgraded Fiserv (FISV) and Paychex (PAYX) to Underweight from Neutral, saying the companies are below-average growers with below-average earnings upside risk.
08/20/18
GUGG
08/20/18
INITIATION
Target $75
GUGG
Neutral
Paychex initiated with a Neutral at Guggenheim
Guggenheim analyst initiated Paychex with a Neutral rating and a price target of $75.
ADP ADP
$148.80

-0.32 (-0.21%)

08/20/18
GUGG
08/20/18
INITIATION
Target $175
GUGG
Buy
ADP initiated with a Buy at Guggenheim
Guggenheim analyst Nandan Amladi initiated Automatic Data Processing with a Buy rating and a price target of $175.
07/17/18
WOLF
07/17/18
INITIATION
Target $175
WOLF
Outperform
ADP initiated with an Outperform at Wolfe Research
Wolfe Research analyst Darrin Peller initiated ADP with an Outperform and $175 price target.
08/10/18
FBCO
08/10/18
INITIATION
Target $160
FBCO
Outperform
ADP initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kevin McVeigh initiated the Business and Professional Services sector, starting ADP with an Outperform rating and $160 price target, telling investors that he is "impressed" with the company's business model, which offers the opportunity to own a unique, HR-related ecosystem and is "comfortable" that recent investments aimed at driving growth have been successful.
SONC Sonic
$43.46

6.85 (18.71%)

09/12/18
OPCO
09/12/18
NO CHANGE
OPCO
Perform
Sonic risk/reward too stretched, pull-back ahead, says Oppenheimer
Oppenheimer analyst Brian Bittner now sees Sonic's risk/reward as too stretched and anticipates a pull-back, based on his analysis. Fundamentally, the analyst believes recent installment of long-term targets tilt aggressively, particularly assumption for 2%-4%-plus same-store sales. He reiterates a Perform rating on the shares.
09/25/18
PIPR
09/25/18
DOWNGRADE
PIPR
Neutral
Sonic downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan downgraded Sonic to Neutral from Overweight citing the company's agreement to be acquired by Inspire Brands.
09/25/18
BARD
09/25/18
NO CHANGE
BARD
M&A interest could put near-term floor under restaurant valuations, says Baird
Baird analyst David Tarantino said Sonic's (SONC) agreement to be acquired by Inspire Brands, which also bought Buffalo Wild Wings last year, underscores that private equity firms continue to have interest in putting money to work in the restaurant sector, which he thinks could help to put a floor on the valuations of publicly-traded restaurant stocks. Among the stocks in the sector that he covers, Tarantino views Jack in the Box (JACK), El Pollo Loco (LOCO), Chuy's (CHUY), Habit Restaurants (HABT) and Potbelly (PBPB) as among those that theoretically could attract buyout interest at their current multiples, he tells investors.
09/25/18
WBLR
09/25/18
DOWNGRADE
WBLR
Market Perform
Sonic downgraded to Market Perform from Outperform at William Blair
William Blair analyst Sharon Zackfia downgraded Sonic to Market Perform citing the takeover by Inspire Brands.
GM General Motors
$33.57

-1.175 (-3.38%)

09/19/18
VERF
09/19/18
NO CHANGE
VERF
Sell
E-tron may not be 'Tesla killer,' but still a 'real risk,' says Vertical Group
After attending Audi's (AUDVF) launch event for its e-tron SUV, Vertical Group analyst Gordon Johnson said he sees Audi's foray in the EV space as "a real risk" to Tesla (TSLA) and other EV auto makers including Chevy (GM) and Ford (F). The Electrify America charging network, owned by a JV of Audi parent Volkswagen (VLKAY) and funded by "Dieselgate," positions Audi's fast-charging ambitions among the most robust, if not the most robust, in the U.S. currently, added Johnson. He does not see Audi's forthcoming e-tron as a "TSLA Killer," but does not "see it a stretch to think of it as a potential TSLA Model X killer," he concludes in his note to investors. Johnson keeps a Sell rating on Tesla shares.
09/11/18
09/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Krystal Biotech (KRYS) initiated with an Overweight at Cantor Fitzgerald. 2. Melinta Therapeutics (MLNT) initiated with a Buy at H.C. Wainwright and Jefferies. 3. Burlington Stores (BURL) initiated with an Overweight at Barclays. 4. General Motors (GM) reinstated with a Neutral at Goldman Sachs. 5. SailPoint (SAIL) initiated with a Market Perform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
GSCO
09/11/18
INITIATION
Target $36
GSCO
Neutral
General Motors reinstated with a Neutral at Goldman Sachs
Goldman Sachs analyst David Tamberrino reinstated coverage of General Motors with a Neutral rating and $36 price target. Before going Not Rated on the name, Goldman had a Sell rating on the shares. The path forward for the shares is "somewhat murky" with a "more challenged" backdrop in North America and growing concerns about the potential for China joint venture income to see further pressure, Tamberrino tells investors in a research note. The analyst sees positives from GM's pickup truck refresh and Korea restructuring accruing in 2019, but still expects a "downward trajectory" to earnings and free cash flow next year. However, he believes the market is prepping for a flat-to-down earnings trajectory and views the stock's risk/reward as balanced at current levels.
09/11/18
RBCM
09/11/18
NO CHANGE
Target $49
RBCM
Outperform
General Motors valuation reflects 'low expectations', says RBC Capital
RBC Capital analyst Joseph Spak kept his Outperform rating and $49 price target on General Motors after hosting meetings with its CEO Mary Barra and CFO Dhivya Suryadevara. The analyst says he remains positive on the company's execution, adding that while investors are focused on China and the direction of earnings in FY19, he believes that the market expectations are already "very low" with forward valuation multiple ex-Cruise and ex-cash at just over 3.5-times earnings. Spak also cites the positives for General Motors from the " recovering volume on light-duty pickups", cost savings, and expectations of strong performance in the mid-size CUV class.
F Ford
$9.39

-0.195 (-2.03%)

08/14/18
NOMU
08/14/18
NO CHANGE
Target $9
NOMU
Neutral
Ford price target lowered to $9 from $10 at Nomura Instinet
Nomura Instinet analyst Anindya Das lowered his price target for Ford to $9 after reducing fiscal 2018 earnings per share estimate by 17% to $1.20. The analyst lowered his outlook for Ford's Asia Pacific operations based on first half of 2018 sales trends and also sees Europe becoming more difficult. Das keeps a Neutral rating on Ford shares.
08/20/18
MSCO
08/20/18
NO CHANGE
Target $15
MSCO
Overweight
Ford risks high, but so is potential reward, says Morgan Stanley
Morgan Stanley analyst Adam Jonas believes Ford announcing plans to spend $11B on restructuring and then canceling its investor day may have may have the unintended consequence of raising expectations for a "big bang" of action. While acknowledging the wide range of potential outcomes, Jonas has an estimate for how Ford could recognize its planned $11B in restructuring charges over a 3-5 year period to achieve annual cost reductions of about $4B, giving it a payback period of just under 3 years that would "usually [be] a very good use of capital" by automotive standards, he tells investors. Jonas maintains an Overweight rating on Ford with a $15 price target, contending that the "risks are high, but so is the potential reward."
09/10/18
SBSH
09/10/18
NO CHANGE
Target $9.9
SBSH
Neutral
Ford price target lowered to $9.90 from $10.50 at Citi
Citi analyst Itay Michaeli lowered his price target for Ford (F) to $9.90 to reflect restructuring-related calls on cash. The analyst keeps a Neutral rating on the shares and continues to maintain his preference for General Motors (GM). Ford faces both fundamental and perception problems, whereas GM just faces the latter, Michaeli tells investors in a research note. While the company must deal with some legitimate China and trade headwinds, the degree of erosion that's implied by the pullback in the shares is overdone, the analyst contends.
FCAU Fiat Chrysler
$18.00

-0.315 (-1.72%)

07/17/18
JEFF
07/17/18
NO CHANGE
Target $25
JEFF
Buy
Santander Consumer, Fiat Chrysler tolling agreement doesn't change much, says Jefferies
Jefferies analyst John Hecht notes that Santander Consumer (SC) and Fiat Chrysler (FCAU) entered a tolling agreement that allows both parties additional time to assess their rights, obligations, claims, etc. while not having to worry about the statute of limitations. The analyst believes the tolling agreement does not change much of what is going on. Nonetheless, Hecht notes that the companies also acknowledged they are working to resolve the matter tied to the captive finance, with the agreement indicating that a resolution on this matter may come in months rather than quarters. He reiterates a Buy rating and $25 price target on Santander Consumer shares.
07/10/18
UBSW
07/10/18
UPGRADE
UBSW
Buy
UBS upgrades Fiat Chrysler to Buy ahead of Q2 results
UBS analyst Patrick Hummel upgraded Fiat Chrysler (FCAU) to Buy from Neutral with a price target of EUR 23. The analyst expects the company's "positive volume/mix impact story" to continue in Q2 even with the ramp of the new RAM 1500 truck unlikely to be completed until Q3. Fiat shares should deliver the best earnings momentum among the European car manufacturers in the coming quarters, Hummel tells investors in a research note.
08/07/18
MSCO
08/07/18
NO CHANGE
Target $1325
MSCO
Overweight
Enterprise value of Alphabet's Waymo raised to $175B at Morgan Stanley
Morgan Stanley analyst Brian Nowak increased his enterprise value estimate for Alphabet's Waymo unit from $75B for ride sharing only to $175B given his analyses for two other emerging business models, namely logistics and licensing. He believes Waymo remains on track to launch an autonomous ride hailing service in Phoenix this year and believes this business could be worth about $80B over the long-term. Partnerships with Walmart (WMT), DDR (DDR) and Peterbilt speak to Waymo's logistics focus, said Nowak, who sees the company potentially having a $90B logistics business. Additionally, he sees a roughly $7B licensing opportunity, pointing to the company's FCA (FCAU) relationship as a model of how companies could pay a license fee to Waymo for its autonomous technology. Given his view of Waymo being a key part of Alphabet's long-term value, Nowak raised his sum of the parts valuation to $1,550 from $1,400. He has an Overweight rating and $1,325 price target on Alphabet shares.
09/12/18
EXAN
09/12/18
UPGRADE
EXAN
Outperform
Fiat Chrysler upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Dominic O'Brien earlier today upgraded Fiat Chrysler to Outperform from Neutral. The shares in afternoon trading are up 3%, or 48c, to $17.79.
BMWYY BMW
$0.00

(0.00%)

05/31/18
MSCO
05/31/18
NO CHANGE
Target $28
MSCO
Overweight
Fiat Chrysler ending Fiat sales in U.S. would be 'sensible,' says Morgan Stanley
Morgan Stanley analyst Adam Jonas said he believes that if Bloomberg is correct and Fiat Chrysler (FCAU) does plan to stop selling Fiat branded cars in North America and China it would be a "sensible recognition" of how to allocate capital over the next five years. BMW (BMWYY), including MINI, sells 21 times more cars in the U.S. than Fiat does, noted Jonas, who said Bloomberg's report appears consistent with his high-level expectation that FCA will send the message that it is cutting investment or possibly exiting areas that don't add shareholder value and "doubling down"' on brands and businesses, like Jeep, that have untapped global potential. Jonas maintains an Overweight rating on Fiat Chrysler shares with a $28 price target.
08/06/18
JPMS
08/06/18
UPGRADE
JPMS
Neutral
BMW upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Jose Asumendi upgraded BMW to Neutral with a price target of EUR 90. The shares are "too cheap to ignore" after the company confirmed its guidance, the analyst tells investors in a research note.
08/10/18
MSCO
08/10/18
UPGRADE
MSCO
Equal Weight
BMW upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Harald Hendrikse upgraded BMW to Equal Weight with a price target of EUR 90.
08/23/18
UBSW
08/23/18
NO CHANGE
UBSW
UBS teardown finds 'numerous' quality issues with Tesla's Model 3
The UBS Evidence Lab tore down the new Tesla (TSLA) Model 3, the 2014 BMW (BMWYY) i3, and 2017 Chevy Bolt from General Motors (GM), UBS analysts led by Colin Langan tell investors in a research note. While Tesla won the first test focused on powertrain and the second test focused on electronics, it came in last on the third test, which focused on fit and finish. Teardown experts noted "numerous" Model 3 quality issues including inconsistent gaps and flushness throughout the car, missing bolts, loose tolerances, and uneven and misaligned spot welds, UBS writes in a research note partially titled "The Revolution is Over." The Model 3 car scored "below average" on the firm's fit and finish quality audit. The results confirm media reports of quality issues and are disappointing for a $49,000 car, UBS writes to investors. The winner of the third test was the Chevy Bolt, with the BMW i3 close behind. UBS believes the Bolt offers good value with a price that's over $10,000 lower than the BMW i3.
XOXO XO Group
$34.91

7.29 (26.39%)

07/31/18
ROTH
07/31/18
NO CHANGE
Target $26
ROTH
Neutral
XO Group price target lowered to $26 from $28 at Roth Capital
Roth Capital analyst Darren Aftahi says that while XO Group's Q2 sales results were in-line, adjusted EBITDA missed consensus estimates. The analyst believes adjusted EBITDA margins and year-over-year growth should trend down over the next two quarters as the company starts to face tougher comps and is expected to pick up marketing and product investment. He lowered his price target for XO shares to $26 from $28 and reiterates a Neutral rating on the name.
05/03/18
RILY
05/03/18
UPGRADE
Target $32
RILY
Buy
XO Group upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Sameet Sinha upgraded XO Group to Buy and raised his price target for the shares to $32 from $19. The company's "solid" Q1 results indicate an acceleration in revenue growth, Sinha tells investors in a post earnings research note.
05/03/18
05/03/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Neutral from Underweight at MUFG with analyst Stephen Bersey saying the company made "material progress" in its subscription transition during the first quarter, which depressed revenue and earnings in the quarter. 2. XO Group (XOXO) upgraded to Buy from Neutral at B. Riley FBR with analyst Sameet Sinha saying the company's "solid" Q1 results indicate an acceleration in revenue growth. 3. Square (SQ) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he views last night's Q1 results as "impressive," highlighting the 31% gross payment volume growth versus last year. 4. Yum! Brands (YUM) upgraded to Outperform from Neutral at Baird. 5. 3M (MMM) upgraded to Outperform from Sector Perform at RBC Capital with analyst Deane Dray saying the 4-month decline in the stock price has taken its valuation to its historical relative PE support level. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/17
10/12/17
DOWNGRADE
Target $20.5

Neutral
XO Group downgraded to Neutral at Roth Capital
As previously reported, Roth Capital analyst Darren Aftahi downgraded Xo Group to Neutral from Buy, with a $20.50 price target, as he believes go forward expectations for modest growth are priced into shares at current levels. The analyst looks for an in-line Q3 when the company reports, driven by double-digit sales growth and improved margins. His checks indicate eCPM headwinds in Q3 for display ads.
ASNA Ascena Retail
$4.47

0.45 (11.19%)

06/05/18
RILY
06/05/18
NO CHANGE
Target $3.5
RILY
Neutral
Ascena Retail price target raised to $3.50 from $2.50 at B. Riley FBR
B. Riley FBR analyst Susan Anderson raised her price target for Ascena Retail Group to $3.50 saying same-store-sales improvement drove earnings to the high end of guidance in Q3. The analyst keeps a Neutral rating on the shares.
TGTX TG Therapeutics
$5.13

-4.125 (-44.59%)

09/25/18
RAJA
09/25/18
DOWNGRADE
RAJA
Outperform
TG Therapeutics downgraded to Outperform from Strong Buy at Raymond James
04/24/18
HCWC
04/24/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics updated data 'remains robust,' says H.C. Wainwright
The updated data from TG Therapeutics' (TGTX) Phase 2 study of ublituximab in patients with relapsing forms of multiple sclerosis "remains robust and consistent with previous updates," H.C. Wainwright analyst Edward White tells investors in a research note. The updated data demonstrates continued safety and efficacy with ublituximab, with sustained 99% median B-cell depletion and 100% reduction in T1 Gd-enhancing lesions, the analyst writes. More importantly, White notes, is that an annualized relapse rate of 0.05 was observed at week 24 in 48 patients, which so far is below the ARR observed with Roche's (RHBBY) Ocrevus, the only approved anti-CD20 monoclonal antibody on the market for multiple sclerosis. The analyst views this morning's data positive and reiterates a Buy rating on TG Therapeutics with a $38 price target.
03/08/18
RHCO
03/08/18
NO CHANGE
Target $38
RHCO
Buy
TG Therapeutics price target increased to $38 from $36 at SunTrust
06/04/18
HCWC
06/04/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics ASCO update an incremental positive, says H.C. Wainwright
H.C. Wainwright analyst Edward White said he believes TG Therapeutics' poster presentation at ASCO further supports his view that umbralisib is a differentiated oral PI3K delta inhibitor. White, who notes that the Phase 3 UNITY-CLL trial remains on target for ORR data this summer, keeps a Buy rating and $38 price target on TG Therapeutics shares.
CTL CenturyLink
$21.05

-1.85 (-8.08%)

07/18/18
07/18/18
DOWNGRADE
Target $17

Market Perform
Adtran downgraded to Market Perform after earnings at Northland
As previously reported, Northland analyst Tim Savageaux downgraded Adtran (ADTN) to Market Perform from Outperform following the company's Q2 report and Q3 revenue guidance that met consensus, stating that he views the shares as fairly valued given that he believes the earnings power needed to support a higher share price is "still a ways off." While Adtran is "slowly but clearly diversifying away" from CenturyLink (CTL), Savageaux has lowered expectations for any snap-back at CenturyLink and sees slower than expected progress at other U.S. Tier 1 telecom companies, he tells investors. The analyst, who reduced his estimates for 2019, cut his price target on Adtran shares to $17 from $20.
08/22/18
MOFT
08/22/18
DOWNGRADE
Target $19
MOFT
Sell
CenturyLink downgraded to Sell from Neutral at MoffettNathanson
MoffettNathanson analyst Nicholas Del Deo downgraded CenturyLink to Sell with a $19 price target. The shares closed yesterday up 13c to $23.98.
09/25/18
OPCO
09/25/18
NO CHANGE
Target $24
OPCO
Outperform
CenturyLink CFO departure raises concerns, says Oppenheimer
Oppenheimer analyst Timothy Horan notes CenturyLink (CTL) has announced that CFO Sunit Patel will depart as of September 28th to join T-Mobile (TMUS) to lead the Sprint (S)/T-Mobile merger and integration efforts. The analyst expects weakness in CenturyLink's stock, as investors will likely be concerned with synergy realization after Patel's departure. While Horan says his departure is disappointing, he believes CenturyLink has a deep management bench, and Jeff Storey, CEO, will continue to be the driving force behind restructuring and expense reductions at the company. He reiterates an Outperform rating and $24 price target on the shares.
08/16/18
RBCM
08/16/18
NO CHANGE
Target $27
RBCM
Outperform
CenturyLink price target raised to $27 from $22 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on CenturyLink to $27 and kept his Outperform rating after its "solid" Q2 results and increased FY18 guidance on "stronger-than-expected synergy realization and benefits from portfolio rationalization". The analyst believes that the company's dividend yield is also safe and its operating expense synergy targets are "beatable". Atkin further notes that although CenturyLink's consumer business is "challenged", it only constitutes about 25% of its combined revenue, and its recent Level 3 Communications transaction helps its "pivot to the enterprise business" with "better underlying economics".
TMUS T-Mobile
$69.46

0.53 (0.77%)

09/13/18
KEYB
09/13/18
NO CHANGE
Target $76
KEYB
Overweight
Possible upside to T-Mobile sub guidance from 600MHz inclusion in iPhone, says KeyBanc
KeyBanc analyst Brandon Nispel notes that T-Mobile (TMUS) CEO John Legere tweeted that the new Apple (AAPL) iPhone models include 600 MHz spectrum, which he finds important given T-Mobile has aggressively built out its 600 MHz spectrum. This should improve the performance of the network, particularly from a coverage perspective, he contends, adding that T-Mobile should be incentivized to aggressively promote the new iPhones to get consumers with mobile devices capable of using the spectrum. Nispel believes an aggressive promotion period from T-Mobile could result in upside to the company's guidance for 3.0M-3.6M branded postpaid net additions. He reiterates an Overweight rating and $76 price target on T-Mobile's shares.
09/13/18
RILY
09/13/18
INITIATION
Target $46
RILY
Buy
Shenandoah initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Zack Silver started Shenandoah Telecommunications (SHEN) with a Buy rating and $46 price target. The analyst sees the company benefiting from the merger between Sprint (S) and T-Mobile (TMUS).
09/20/18
OPCO
09/20/18
NO CHANGE
OPCO
Outperform
T-Mobile, AT&T 'top large-cap picks' in telecom, says Oppenheimer
Oppenehimer analyst Timothy Horan previewed the telecom outlook for 2H18, telling investors in a research note that he believes the communications sector has bottomed relative to the market and expects to see stronger 2H performance. Horan says T-Mobile (TMUS) and AT&T (T) are his top large-cap picks, and Boingo Wireless (WIFI) and Zayo Group (ZAYO) will also benefit as carriers invest in their networks in preparation for 5G. Horan also expects T-Mobile to outperform as it continues to take share and see margin improvement.
S Sprint
$6.40

0.01 (0.16%)

06/28/18
06/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Air Transport Services (ATSG) upgraded to Buy from Hold at Stifel with analyst David Ross saying shares are attractive at current levels given long-term growth prospects. 2. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche stating that recent conversations with some of his DC contacts have made him more optimistic that a deal to merge with Sprint (S) could be approved. 3. Talend (TLND) upgraded to Buy from Neutral at with analyst Tyler Radke saying a survey of Chief Data Officers shows "strong spending signals" while the company's competitive backdrop is favorable amid "increasing cloud tailwinds". 4. Regions Financial (RF) upgraded to Neutral from Underperform at Baird with analyst David George citing the recent pullback, which he thinks has made the valuation more reasonable. 5. Twilio (TWLO) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the pullback in the stock price has created a more favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
SBSH
08/07/18
NO CHANGE
SBSH
Citi credit sees 80% chance of T-Mobile, Sprint merger approval
Citi credit analyst David Phipps believes T-Mobile (TMUS) and Sprint (S) have an 80% chance of winning approval for their proposed merger. The market regularly puts merger approval odds at 50/50, Phipps tells investors in a fixed income research note. The analyst remains bullish on Sprint credit.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.